RJA
GNPX icon

Raymond James & Associates’s Genprex GNPX Stock Holding History

Raymond James & Associates’s Portfolio GNPX Stock Details GNPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Hold
0
– -$49K – 4175
2021
Q2 		– Sell
-1
Closed -$164K – 3917
2021
Q1 		$106K Hold
1
– – ﹤0.01% 3769
2020
Q4 		$92K Buy
+1
New +$155K ﹤0.01% 3570
2020
Q3 		– Hold
0
– – – 3474

Other funds holding GNPX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Cypress Capital Franklin, Tennessee $370M AUM 16.36% 1-Year Est. Return

Raymond James & Associates's GNPX Position: Q3 2021 in Review

Raymond James & Associates held its Genprex (GNPX) position steady in Q3 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4175.

Raymond James & Associates first reported a position in GNPX in Q4 2020 and has held it in 2 quarters since. The position peaked at $106K in Q1 2021. 28 funds tracked by Wall St. Rank hold GNPX as of Q3 2021.

  • Raymond James & Associates held 0 shares of Genprex worth $0 as of Q3 2021.
  • Raymond James & Associates left its Genprex share count unchanged in Q3 2021.
  • Genprex made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2021, its #4175 holding.
  • Raymond James & Associates first reported a position in Genprex in Q4 2020 and has held it in 2 quarters since.
  • Raymond James & Associates's Genprex position peaked at $106K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Genprex as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.